SiRNA for inhibiting interleukin-1alpha and application thereof
By designing and modifying the nucleotide sequence of siRNA, the problem of limited effect of existing interleukin-1α inhibitors is solved, and efficient inhibition of interleukin-1α is achieved, with significant potential for the treatment of inflammatory diseases and tumors. .
Patent Information
- Application Number
- CN202411499440.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-25
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-10-25
AI Technical Summary
Existing interleukin-1α inhibitors have limited effectiveness in the treatment of inflammatory diseases and tumors, and there are problems of insufficient targeting and effectiveness.
A siRNA was developed to complement the double-stranded region in a specific manner by designing the nucleotide sequences of its sense and antisense strands and to improve the mediation of leukocytes by methoxy, fluoro and phosphorothioate groups. Inhibitory activity of cin-1α.
It has achieved efficient inhibition of interleukin-1α, and has significant potential for the treatment of inflammatory diseases and tumors, especially at concentrations of 0.1~10 nM.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention relates to siRNA for inhibiting interleukin-1α and application thereof, belonging to the field of biotechnology. Background Art
[0002] Interleukin-1α (IL-1α) is encoded by the IL1A gene and is a cytokine in the chemokine family with multiple biological functions. Interleukin-1α is a multifunctional signaling molecule that is widely present in the body. In cells, it acts as a transcription factor that can regulate cell growth and differentiation, while outside cells, it participates in the body's inflammatory response. Both the precursor and mature forms of interleukin-1α are biologically active, but the mature form of interleukin-1α is more biologically active.
[0003] Studies have shown that interleukin-1α can drive autoinflammatory diseases such as rheumatoid arthritis and systemic lupus erythematosus. The most consistent clinical feature of this type of autoinflammatory disease mediated by interleukin-1α is paroxysmal or chronic systemic or tissue inflammation. Commonly affected areas include the skin and musculoskeletal system. Therefore, interleukin-1α can be used as a therapeutic target for autoinflammatory diseases. Interleukin-1α inhibitors can effectively treat a variety of autoinflammatory diseases mediated by interleukin-1α, including rheumatoid arthritis and systemic lupus erythematosus.
[0004] In addition to driving the occurrence of autoinflammatory diseases, interleukin-1α is also involved in the occurrence and development of tumors. For example, interleukin-1α has long been shown to be associated with inflammation-induced carcinogenesis, and interleukin-1α has been shown to promote the growth and metastasis of tumors such as melanoma, myeloma, ovarian cancer, and breast cancer. Further studies have found that the tumor-promoting mechanism of interleukin-1α is very complex, including the recruitment and immunosuppression of myeloid cells, the promotion of angiogenesis and activation of endothelial cells, and the inclination of lymphoid cell differentiation. At this stage, many new studies have shown that blocking with interleukin-1α inhibitors in the early stages of tumor development can effectively slow tumor growth. Therefore, interleukin-1α inhibitors can be used for the treatment of tumors.
[0005] RNA interference (RNAi) refers to the highly conserved phenomenon of highly efficient and specific degradation of homologous mRNA induced by double-stranded RNA (dsRNA) during evolution. Small interfering RNA (siRNA) is a double-stranded RNA of 20 to 25 nucleotides in length that can mediate the silencing of specific genes through the RNA interference (RNAi) mechanism. In the RNAi pathway, siRNA interferes with gene expression by hybridizing with complementary mRNA molecules. This interference triggers mRNA degradation and inhibits the expression of specific genes. This specific way of regulating gene expression allows siRNA to be used as a targeted therapeutic drug to specifically regulate the expression of disease-related genes and achieve the purpose of treating diseases. If siRNA that can effectively inhibit the expression of interleukin-1α can be developed, it will be a more effective and targeted drug for the treatment of inflammatory diseases and cancer. Summary of the invention
[0006] To solve the above problems, the present invention provides an siRNA for inhibiting interleukin-1α, wherein the siRNA contains a sense chain and an antisense chain; the sense chain and the antisense chain are at least partially reverse-complementary to form a double-stranded region; the sense chain of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in any one of SEQ ID NOs.1 to 17; and the antisense chain of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in any one of SEQ ID NOs.18 to 34.
[0007] In one embodiment of the present invention, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.1, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.18; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.2, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.19; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.3, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.20; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.4, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.21; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.5, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.22; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.6, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.23; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.7, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.24; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.8, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.25; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.9, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.26; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.10, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.27; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.11, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.28; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.12, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.29; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.13, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.30; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.14, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.31; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.15, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.32; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.16, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.33; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.17, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.34.
[0008] In one embodiment of the present invention, the nucleotide sequence of the sense strand of the siRNA is shown as SEQ ID NO.1, and the nucleotide sequence of the antisense strand is shown as SEQ ID NO.18; Alternatively, the nucleotide sequence of the sense strand of the siRNA is as shown in SEQ ID NO.2, and the nucleotide sequence of the antisense strand is as shown in SEQ ID NO.19; Alternatively, the nucleotide sequence of the sense strand of the siRNA is as shown in SEQ ID NO.3, and the nucleotide sequence of the antisense strand is as shown in SEQ ID NO.20; Alternatively, the nucleotide sequence of the sense strand of the siRNA is as shown in SEQ ID NO.4, and the nucleotide sequence of the antisense strand is as shown in SEQ ID NO.21; Alternatively, the nucleotide sequence of the sense strand of the siRNA is as shown in SEQ ID NO.5, and the nucleotide sequence of the antisense strand is as shown in SEQ ID NO.22; Alternatively, the nucleotide sequence of the sense strand of the siRNA is as shown in SEQ ID NO.6, and the nucleotide sequence of the antisense strand is as shown in SEQ ID NO.23; Alternatively, the nucleotide sequence of the sense strand of the siRNA is as shown in SEQ ID NO.7, and the nucleotide sequence of the antisense strand is as shown in SEQ ID NO.24; Alternatively, the nucleotide sequence of the sense strand of the siRNA is as shown in SEQ ID NO.8, and the nucleotide sequence of the antisense strand is as shown in SEQ ID NO.25; Alternatively, the nucleotide sequence of the sense strand of the siRNA is as shown in SEQ ID NO.9, and the nucleotide sequence of the antisense strand is as shown in SEQ ID NO.26; Alternatively, the nucleotide sequence of the sense strand of the siRNA is as shown in SEQ ID NO.10, and the nucleotide sequence of the antisense strand is as shown in SEQ ID NO.27; Alternatively, the nucleotide sequence of the sense strand of the siRNA is as shown in SEQ ID NO.11, and the nucleotide sequence of the antisense strand is as shown in SEQ ID NO.28; Alternatively, the nucleotide sequence of the sense strand of the siRNA is as shown in SEQ ID NO.12, and the nucleotide sequence of the antisense strand is as shown in SEQ ID NO.29; Alternatively, the nucleotide sequence of the sense strand of the siRNA is as shown in SEQ ID NO.13, and the nucleotide sequence of the antisense strand is as shown in SEQ ID NO.30; Alternatively, the nucleotide sequence of the sense strand of the siRNA is as shown in SEQ ID NO.14, and the nucleotide sequence of the antisense strand is as shown in SEQ ID NO.31; Alternatively, the nucleotide sequence of the sense strand of the siRNA is as shown in SEQ ID NO.15, and the nucleotide sequence of the antisense strand is as shown in SEQ ID NO.32; Alternatively, the nucleotide sequence of the sense strand of the siRNA is as shown in SEQ ID NO.16, and the nucleotide sequence of the antisense strand is as shown in SEQ ID NO.33; Alternatively, the nucleotide sequence of the sense strand of the siRNA is shown as SEQ ID NO.17, and the nucleotide sequence of the antisense strand is shown as SEQ ID NO.34.
[0009] In one embodiment of the present invention, at least one nucleotide in the sense strand or the antisense strand of the siRNA is a modified nucleotide.
[0010] In one embodiment of the present invention, all nucleotides in the sense strand and / or antisense strand of the siRNA are modified nucleotides, and these modifications on the nucleotide groups will not lead to a significant weakening or loss of the function of the siRNA disclosed herein to inhibit interleukin-1α gene expression.
[0011] In one embodiment of the present invention, the modification comprises methoxy modification, fluorine modification and / or phosphorothioate linkage.
[0012] In one embodiment of the present invention, the "phosphorothioate linkage" means that at least a portion of the phosphate groups in the phosphate-sugar backbone of at least one single strand in the sense strand and the antisense strand of the siRNA is a phosphate group having a modified group.
[0013] In one embodiment of the present invention, the phosphate group having a modified group is a phosphorothioate group formed by replacing at least one oxygen atom in the phosphodiester bond in the phosphate group with a sulfur atom.
[0014] In one embodiment of the present invention, the fluorinated modified nucleotides are located in the antisense strand and the sense strand of the nucleotide sequence, and, in the direction from the 5' end to the 3' end, at least the 7th, 8th, and 9th nucleotides of the sense strand are fluorinated modified nucleotides, and at least the 2nd, 6th, 14th, and 16th nucleotides of the antisense strand are fluorinated modified nucleotides; The methoxy-modified nucleotides are located in the antisense strand and the sense strand of the nucleotide sequence, and, in the direction from the 5' end to the 3' end, at least the 1st, 2nd, 3rd, 4th, 5th, 6th, 10th, 11th, 12th, 13th, 14th, 15th, 16th, 17th, 18th, 19th nucleotides of the sense strand are methoxy-modified nucleotides, and at least the 1st, 3rd, 4th, 5th, 7th, 8th, 9th, 10th, 11th, 12th, 13th, 15th, 17th, 18th, 19th nucleotides of the antisense strand are methoxy-modified nucleotides; The nucleotides linked by the thiophosphate groups are located in the antisense strand and the sense strand of the nucleotide sequence, and, in the direction from the 5' end to the 3' end, at least the 1st and 2nd, and the 2nd and 3rd nucleotides of the sense strand are linked by the thiophosphate groups, and at least the 1st and 2nd, the 2nd and 3rd, the 19th and 20th, and the 20th and 21st nucleotides of the antisense strand are linked by the thiophosphate groups.
[0015] The present invention also provides a recombinant plasmid, which expresses the above siRNA.
[0016] In one embodiment of the present invention, the vector of the recombinant plasmid includes at least one of a viral vector or a non-viral vector; the viral vector includes at least one of a flavivirus vector, a retrovirus vector, a phage vector, an adenovirus vector, an adeno-associated virus vector, a vaccinia virus vector, a hybrid virus vector, a baculovirus vector, a herpes simplex virus vector or a lentivirus vector; the non-viral vector includes a plasmid vector.
[0017] In one embodiment of the present invention, the plasmid vector comprises a pUC plasmid, a derivative plasmid of a pUC plasmid, a pAAV plasmid, a derivative plasmid of a pAAV plasmid, a PGEM plasmid and / or a derivative plasmid of a PGEM plasmid.
[0018] In one embodiment of the present invention, the preparation method of the recombinant plasmid is: designing shRNA according to siRNA; connecting shRNA with a linearized vector to obtain the recombinant plasmid.
[0019] The present invention also provides a host cell, wherein the genome of the host cell is integrated with the above siRNA; or the host cell carries the above recombinant plasmid.
[0020] In one embodiment of the present invention, the host cell comprises fungi, bacteria, plant cells and / or animal cells.
[0021] The present invention also provides the use of the above siRNA, the above recombinant plasmid or the above host cell in the preparation of a drug for preventing and / or treating a disease, characterized in that the disease is a disease related to the expression of interleukin-1α.
[0022] In one embodiment of the present invention, the disease associated with the expression of interleukin-1α includes cancer and / or inflammatory disease.
[0023] In one embodiment of the present invention, the cancer comprises melanoma, myeloma, ovarian cancer and / or breast cancer.
[0024] In one embodiment of the present invention, the inflammatory disease comprises an autoinflammatory disease; the autoinflammatory disease comprises rheumatoid arthritis and / or systemic lupus erythematosus.
[0025] The present invention also provides an interleukin-1α inhibitor, the components of which include the above-mentioned siRNA, the above-mentioned recombinant plasmid and / or the above-mentioned host cell.
[0026] In one embodiment of the present invention, the inhibitor further comprises a pharmaceutically acceptable excipient; the pharmaceutically acceptable excipient comprises a carrier, a diluent, a binder and / or a lubricant.
[0027] The present invention also provides a drug for preventing and / or treating a disease, wherein the disease is a disease associated with the expression of interleukin-1α; the components of the drug include the above-mentioned siRNA, the above-mentioned recombinant plasmid and / or the above-mentioned host cell.
[0028] In one embodiment of the present invention, the disease associated with the expression of interleukin-1α includes cancer and / or inflammatory disease.
[0029] In one embodiment of the present invention, the cancer comprises melanoma, myeloma, ovarian cancer and / or breast cancer.
[0030] In one embodiment of the present invention, the inflammatory disease comprises an autoinflammatory disease; the autoinflammatory disease comprises rheumatoid arthritis and / or systemic lupus erythematosus.
[0031] In one embodiment of the present invention, the composition of the drug further comprises a pharmaceutically acceptable excipient; the pharmaceutically acceptable excipient comprises a carrier, a diluent, a binder and / or a lubricant.
[0032] The technical solution of the present invention has the following advantages: The present invention provides an siRNA for inhibiting interleukin-1α, wherein the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in any one of SEQ ID NOs. 1 to 17; and the antisense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in any one of SEQ ID NOs. 18 to 34. Experiments have shown that the siRNAs all have high inhibitory activity against interleukin-1α, and therefore, the siRNAs have great application prospects in the preparation of drugs for preventing and / or treating diseases related to the expression of interleukin-1α (such as cancer and inflammatory diseases, etc.).
[0033] Furthermore, the nucleotides at positions 7, 8, and 9 of the sense strand of the siRNA are fluorine-modified nucleotides, the nucleotides at positions 1, 2, 3, 4, 5, 6, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19 are methoxy-modified nucleotides, and the nucleotides at positions 1 and 2, and at positions 2 and 3 are linked by thiophosphate groups; the nucleotides at positions 2, 6, 14, and 16 of the antisense strand of the siRNA are fluorine-modified nucleotides, the nucleotides at positions 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, and 21 are methoxy-modified nucleotides, and the nucleotides at positions 1 and 2, positions 2 and 3, positions 19 and 20, and positions 20 and 21 are linked by thiophosphate groups. Experiments have shown that modified siRNA has high inhibitory activity against interleukin-1α at concentrations of 0.1~10 nM. Therefore, modified siRNA has great application prospects in the preparation of drugs for preventing and / or treating diseases related to the expression of interleukin-1α (such as cancer and inflammatory diseases). DETAILED DESCRIPTION
[0034] The following examples are provided for a better understanding of the present invention, but are not intended to limit the best mode of implementation, nor to limit the content and protection scope of the present invention. Any product identical or similar to the present invention obtained by anyone under the inspiration of the present invention or by combining the features of the present invention with other prior arts shall fall within the protection scope of the present invention.
[0035] If no specific experimental steps or conditions are specified in the following examples, the conventional experimental steps or conditions described in the literature in the field can be used. If no manufacturer is specified for the reagents or instruments used, they are all conventional reagent products that can be purchased commercially.
[0036] In the following embodiments, capital letters C, G, U, and A represent ribonucleotides; lowercase letter m represents that the nucleotide adjacent to the left of the letter m is a methoxy-modified nucleotide; lowercase letter f represents that the nucleotide adjacent to the left of the letter f is a fluorinated-modified nucleotide; lowercase letter s represents that the nucleotides adjacent to the left and right of the letter s are modified with a phosphorothioate group.
[0037] Example 1: A siRNA for inhibiting interleukin-1α This embodiment provides a siRNA for inhibiting interleukin-1α. The nucleotide sequence of the siRNA is designed based on the target mRNA, as shown in Table 1.
[0038] Table 1. siRNAs and their sequences that inhibit interleukin-1α
[0039] Example 2: A siRNA for inhibiting interleukin-1α This embodiment provides an siRNA for inhibiting interleukin-1α. The siRNA is prepared in accordance with Embodiment 1, wherein the nucleotides at positions 7, 8, and 9 of the sense strand of the siRNA are replaced with fluoro-modified nucleotides, the nucleotides at positions 1, 2, 3, 4, 5, 6, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19 are replaced with methoxy-modified nucleotides, and the nucleotides at positions 1 and 2, and between positions 2 and 3 are replaced with thiocyanate-modified nucleotides. The nucleotides at positions 2, 6, 14, and 16 of the antisense strand of the siRNA are replaced with fluorinated nucleotides, the nucleotides at positions 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, and 21 are replaced with methoxy-modified nucleotides, and the nucleotides at positions 1 and 2, positions 2 and 3, positions 19 and 20, and positions 20 and 21 are linked via thiophosphate groups, as shown in Table 2.
[0040] Table 2. siRNAs and their sequences that inhibit interleukin-1α
[0041] Experimental Example 1: Detection of inhibitory activity of siRNA for inhibiting interleukin-1α This experimental example provides an inhibitory activity detection experiment of siRNA for inhibiting interleukin-1α. The experimental process is as follows: Hey cells (human ovarian cancer cells, purchased from Wuhan Punosai Life Science Technology Co., Ltd., catalog number: CL-0671) were inoculated into DMEM medium (purchased from Transgen Biotech, catalog number FI101-01) containing 10% (v / v) fetal bovine serum (FBS) and 1% (v / v) penicillin-streptomycin mixture (Penicillin-Streptomycin, purchased from Gibco, catalog number 15140122), and cultured in a 5% (v / v) CO2, 37°C cell culture incubator for 48 h; after the culture, the cultured Hey cells were digested with trypsin (purchased from GIBCO, catalog number 25200-072); after the digestion, the digested Hey cells were first rinsed with PBS buffer, and then the digested Hey cells were resuspended in DMEM medium to obtain a cell concentration of 3×10 5 Cell suspension of 100 cells / mL; Use opti-MEM (purchased from Gibco, catalog number 31985-070) to dilute different siRNAs to obtain siRNA dilution solutions containing different siRNAs; mix 25 μL of opti-MEM with 0.25 μL of Lipofectamine RNAiMAX transfection reagent (purchased from Thermo Fisher, catalog number 11668-019) to obtain transfection reagent dilution solution; take 25 μL of siRNA dilution solutions containing different siRNAs and mix them with transfection reagent dilution solution, and let stand at room temperature (25°C) for 15 min to obtain transfection solutions containing different siRNAs; After the cell suspension was inoculated into a 96-well plate at an inoculation volume of 50 μL / well, the transfection reagent control group (MOCK), IL1A-1M1 experimental group, IL1A-2M1 experimental group, IL1A-3M experimental group, IL1A-4M1 experimental group, IL1A-5M1 experimental group, IL1A-6M1 experimental group, IL1A-7M1 experimental group, IL1A-8M1 experimental group, IL1A-9M1 experimental group, IL1A-10M1 experimental group, IL1A-11M1 experimental group, IL1A-12M1 experimental group, IL1A-13M1 experimental group, IL1A-14M1 experimental group, IL1A-15M1 experimental group, IL1A-16M1 experimental group and IL1A-17M1 experimental group were set up in the 96-well plate, with 4 replicate wells in each group; After the setup was completed, 50 μL of transfection solution containing different siRNAs was added to the wells of the experimental groups (IL1A-1M1 experimental group was given transfection solution containing IL1A-1M1, IL1A-2M1 experimental group was given transfection solution containing IL1A-2M1, and so on, where the final concentration of siRNA in the well was 10 nM), and 50 μL of transfection solution without any siRNA was added to the wells of the transfection reagent control group (MOCK), and the cells were cultured in a 5% (v / v) CO2, 37°C cell culture incubator for 48 h for transfection; after the transfection was completed, the liquid in the wells was discarded, the cells were collected, and the total RNA in the cells was extracted using a magnetic bead method cell total RNA extraction kit (Jima Gene-E31008-96) to obtain RNA extract; According to Table 3, the genomic DNA removal reaction system was configured to remove the genomic DNA in the RNA extract to obtain a treated RNA extract (the reaction procedure for removing genomic DNA was: 42°C, 2 min); according to Table 4, the cDNA synthesis reaction system was configured to reverse transcribe the total RNA in the treated RNA extract to obtain a cDNA solution (the conditions for reverse transcription were: 50°C, 15 min; 85°C, 2 min); the cDNA solution was diluted 5 times with enzyme-free water, and the diluted cDNA solution was used as a template, and the gene encoding glyceraldehyde-3-phosphate dehydrogenase (HGAPDH gene) was used as an internal reference gene. According to Table 5, the RT-qPCR probe method reaction system was configured (the primers used in the reaction system are shown in Table 6), and the fluorescence quantitative PCR reaction was performed on Lightcycler®480II using the configured RT-qPCR probe method reaction system (the amplification procedure for the fluorescence quantitative PCR reaction was: 95°C pre-denaturation for 10 min, 95°C denaturation for 30 s, 60°C annealing for 30 s, 72°C extension for 30 s, after repeating the above denaturation, annealing and extension process for 40 times, a product W containing the amplified target gene IL1A and the internal reference gene GAPDH was obtained; the product W was then subjected to an incubation program of 95°C for 15 s, 60°C for 1 min, and 95°C for 15 s, and the melting curves of the target gene IL1A and the internal reference gene GAPDH in the product W were collected by a real-time fluorescence quantitative PCR instrument, respectively, to obtain the Ct values of the target gene (IL1A mRNA) of the test group and the internal reference gene (GAPDH) of the test group; the comparative Ct (ΔΔCt) method was used to perform relative quantitative calculation of the target gene (IL1A mRNA) in each test group, and the calculation results are shown in Table 7; The relative quantification method is as follows: ΔCt(test group)=Ct(test group target gene)-Ct(test group reference gene); ΔCt(control group)=Ct(control group target gene)–Ct(control group internal reference gene); ΔΔCt(test group)=ΔCt(test group)-ΔCt(control group average); ΔΔCt(control group)=ΔCt(control group)-ΔCt(control group average); When calculating, the expression level of IL1A mRNA in the test group was normalized with the transfection reagent control group as the benchmark, and the expression level of IL1A mRNA in the transfection reagent control group was defined as 100%; The relative expression level of IL1A mRNA in the test group = 2 -ΔΔCt(测试组) ×100%; For the same test group siRNA, the average relative expression level of IL1A mRNA in the test group at each concentration was the arithmetic mean of the relative expression levels of the three culture wells at that concentration; The inhibition rate of siRNA on IL1A mRNA expression was calculated according to the following equation: inhibition rate = (1-relative expression level of IL1A mRNA in the test group) × 100%.
[0042] As can be seen from Table 7, compared with the transfection reagent control group (MOCK), except IL1A-9M1, IL1A-1M1~IL1A-8M1 and IL1A-10M1~IL1A-17M1 all have inhibitory activity on interleukin-1α, among which IL1A-1M1, IL1A-2M1, IL1A-3M1, IL1A-4M1, IL1A-5M1, IL1A-6M1, IL1A-7M1, IL1A-10M1, IL1A-11M1, IL1A-12M1, IL1A-16M1 and IL1A-17M1 have higher inhibitory activity on interleukin-1α.
[0043] Table 3. Genome removal reaction system
[0044] Table 4 cDNA synthesis reaction system
[0045] Table 5. RT-qPCR probe method reaction system
[0046] Table 6. Primer information
[0047] Table 7. Inhibition rate of IL1A mRNA expression by different siRNAs (IL1A-1M1~IL1A-21M1)
[0048] Experimental Example 2: Detection of inhibitory activity of siRNA for inhibiting interleukin-1α at different concentrations This experimental example provides an inhibitory activity detection experiment of siRNA for inhibiting interleukin-1α at different concentrations. The experimental process is as follows: On the basis of Experimental Example 1, a blank control group (BLANK) and a negative control group (NC) were added, and IL1A-1M1, IL1A-2M1, IL1A-3M1, IL1A-4M1, IL1A-5M1, IL1A-7M1, IL1A-12M1, IL1A-16M1 and IL1A-17M1 with higher inhibitory activity were selected as research objects. During the experiment, the concentration of siRNA in the well was replaced from 10 nM to 0.1 nM and 1 nM, respectively, by adjusting the concentration of siRNA after dilution with opti-MEM. Among them, the blank control group (BLANK) was not added to any reagent in the well as a blank control, and the negative control group (NC) was added to the well with 50 μL of transfection solution containing NC (the final concentration of NC in the well was 10 nM) as a negative control. The experimental results are shown in Table 8.
[0049] As shown in Table 8, compared with the blank control group (BLANK) and the transfection reagent control group (MOCK), IL1A-1M1, IL1A-2M1, IL1A-3M1, IL1A-4M1, IL1A-5M1, IL1A-7M1, IL1A-12M1, IL1A-16M1 and IL1A-17M1 all have high inhibitory activity against interleukin-1α at lower concentrations of 0.1~1 nM.
[0050] Table 8. Inhibition rate of IL1A mRNA expression level by different siRNAs (IL1A-1M1 / IL1A-2M1 / IL1A-3M1 / IL1A-4M1 / IL1A-5M1 / IL1A-7M1 / IL1A-12M1 / IL1A-16M1 / IL1A-17M1) at different concentrations (0.1 nM, 1 nM and 10 nM)
[0051] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.
Claims
1. A siRNA for inhibiting interleukin-1α, It is characterized in that The siRNA contains a sense strand and an antisense strand; the sense strand and the antisense strand are at least partially reverse-complementary to form a double-stranded region; the sense strand of the siRNA comprises a nucleic acid molecule with a nucleotide sequence as shown in any one of SEQ ID NOs.1 to 17; the antisense strand of the siRNA comprises a nucleic acid molecule with a nucleotide sequence as shown in any one of SEQ ID NOs.18 to 34.
2. The siRNA according to claim 1, It is characterized in that The sense strand of the siRNA comprises a nucleic acid molecule with a nucleotide sequence as shown in SEQ ID NO.1, and the antisense strand comprises a nucleic acid molecule with a nucleotide sequence as shown in SEQ ID NO.18; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.2, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.19; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.3, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.20; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.4, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.21; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.5, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.22; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.6, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.23; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.7, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.24; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.8, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.25; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.9, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.26; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.10, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.27; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.11, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.28; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.12, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.29; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.13, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.30; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.14, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.31; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.15, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.32; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.16, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.33; Alternatively, the sense strand of the siRNA comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.17, and the antisense strand comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.
34.
3. The siRNA according to claim 1 or 2, It is characterized in that At least one nucleotide in the sense strand or the antisense strand of the siRNA is a modified nucleotide.
4. The siRNA according to claim 3, It is characterized in that The modifications include methoxy modification, fluorine modification and / or phosphorothioate linkage.
5. The siRNA according to claim 4, It is characterized in that The fluorinated modified nucleotides are located in the antisense strand and the sense strand of the nucleotide sequence, and, in the direction from the 5' end to the 3' end, at least the 7th, 8th, and 9th nucleotides of the sense strand are fluorinated modified nucleotides, and at least the 2nd, 6th, 14th, and 16th nucleotides of the antisense strand are fluorinated modified nucleotides; The methoxy-modified nucleotides are located in the antisense strand and the sense strand of the nucleotide sequence, and, in the direction from the 5' end to the 3' end, at least the 1st, 2nd, 3rd, 4th, 5th, 6th, 10th, 11th, 12th, 13th, 14th, 15th, 16th, 17th, 18th, 19th nucleotides of the sense strand are methoxy-modified nucleotides, and at least the 1st, 3rd, 4th, 5th, 7th, 8th, 9th, 10th, 11th, 12th, 13th, 15th, 17th, 18th, 19th nucleotides of the antisense strand are methoxy-modified nucleotides; The nucleotides linked by the thiophosphate groups are located in the antisense strand and the sense strand of the nucleotide sequence, and, in the direction from the 5' end to the 3' end, at least the 1st and 2nd, and the 2nd and 3rd nucleotides of the sense strand are linked by the thiophosphate groups, and at least the 1st and 2nd, the 2nd and 3rd, the 19th and 20th, and the 20th and 21st nucleotides of the antisense strand are linked by the thiophosphate groups.
6. A recombinant plasmid, It is characterized in that The recombinant plasmid expresses the siRNA according to any one of claims 1 to 5.
7. A host cell, It is characterized in that The genome of the host cell is integrated with the siRNA according to any one of claims 1 to 5; or the host cell carries the recombinant plasmid according to claim 6.
8. Use of the siRNA according to any one of claims 1 to 5, the recombinant plasmid according to claim 6 or the host cell according to claim 7 in the preparation of a drug for preventing and / or treating a disease, It is characterized in that The disease is a disease associated with the expression of interleukin-1α.
9. An interleukin-1α inhibitor, It is characterized in that The inhibitor comprises the siRNA according to any one of claims 1 to 5, the recombinant plasmid according to claim 6 and / or the host cell according to claim 7.
10. A drug for preventing and / or treating a disease, It is characterized in that The disease is a disease associated with the expression of interleukin-1α; the components of the drug include the siRNA according to any one of claims 1 to 5, the recombinant plasmid according to claim 6 and / or the host cell according to claim 7.
Citation Information
Patent Citations
Use of apoptosis-specific eif-5a sirna to down regulate expression of proinflammatory cytokines to treat sepsis
CN101384718A
Method for promoting human keratinocyte to express inflammatory factor IL-alpha
CN105111300A
Immune cells having increased immunity or resistance to an immunosuppressive cytokine and use of the same
CN108289912A
Improved inhibitor nucleic acids
CN1849396A
